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cTn assays; and that there is a lack of consensus and no Canadian guide-
lines on hs-cTn result interpretation [6]. This gap could lead to groups
and/or individuals developing speciﬁc approaches that may or may
not be data driven. In the interim, laboratory guidelines on hs-cTn-
assay cutoffs have been published [7] and knowledge translation and
dissemination events have recently been held in Canada and the
United Kingdom to discuss, share and exchange data, ideas and
thoughts on the use of hs-cTn assays in the acute care setting. Through
a dissemination grant from the Canadian Institutes of Health ResearchNeed for a workshop on high-sensitivity cardiac troponin
Presently in clinical practice there are two putative high-sensitivity
cardiac troponin (hs-cTn) assays available outside the United States
(Abbott Diagnostics hs-cTnI and Roche Diagnostics hs-cTnT) with
many more research hs-cTn assays available in the market place.
Despite the hs-cTn assays achieving regulatory approval, there is still
much uncertainty on their proper use in the acute care setting [1].
Moreover, there appear to be regional differences in the uptake and in
the application of hs-cTn assays for clinical care. Speciﬁcally, within
Canada there is a paucity of published data on hs-cTn performance on
patients with suspected acute coronary syndrome (ACS) in the emer-
gency department, with a published report from the Canadian Agency
for Drugs and Technologies in Health (CADTH) [2], only referencing
small Canadian studies in this area [3–5]. In fact, the CADTH's Health
Technology Expert Review Panel statement “…encourages further
research exploring different clinical algorithms to optimize patient
and health system outcomes associated with high-sensitivity cardiac
troponin testing.” [6]. Their statement was based on the fact that therencer Centre (Core Lab Section)
a. Fax: +1 905 575 2581.
ty of Clinical Chemists. Published(CIHR), a two-day workshop on the hs-cTn assays was held on May 30
and 31, 2014 where CIHR-funded researchers and international experts
assembled to discuss and interpret the ﬁndings of recent and ongoing
studies involving the hs-cTn assays.
Objectives for hs-cTn workshop
Thepurpose of theworkshopwas to disseminate knowledge regard-
ing the hs-cTn assays that will further the discussion in this area via the
following three speciﬁc objectives:
1. Knowledge dissemination on what constitutes a ‘high-sensitivity’
cardiac troponin assay;
2. Dissemination of Canadian research ﬁndings and discussion with
respect to the rest of the world research ﬁndings;
3. A document to be published on gaps in hs-cTn testing in a clinical
journal.
Participants attending theworkshop (in person or via internet)were
from across Canada, the United States, Europe and Australia and includ-
ed physicians, clinical biochemists, medical laboratory technologists,
laboratory directors, administration, clinical and veterinary researchers,
university researchers, regulatory agencies, and industry representa-
tives. One area, however, where there appears to be growing consensus
is what constitutes a hs-cTn assay. Speciﬁcally for the hs-cTn assays
≥50% of healthy subjects will have measurable cardiac troponin
concentrations (reported in ng/L units) [1,7]; thus physicians and labo-
ratory professionals will need to become accustomed to managingby Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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trations, respectively.
Gaps in hs-cTn testing
Despite the central role of cardiac troponin to aid in the diagnosis of
myocardial infarction [8], there is still much data needed to fully
optimize the sensitivity/utility of the hs-cTn assays in the diagnosis or
exclusion of ACS. Moreover, there are many other hospitalized popula-
tions where hs-cTn may play an important role in risk stratiﬁcation
and identiﬁcation of myocardial injury. To that end, we have identiﬁed
areas where there are knowledge gaps and where further research is
necessary for clinicians to fully utilize the results yielded by the hs-cTn
assays:
1. The calculation and clinical utility of the 99th percentile for the
“healthy population” as measured by the hs-cTn assays. This is an
on-going and evolving area where the use of additional laboratory
markers and cardiovascular imaging will drastically change the
99th percentile cutoff [9]. Additional data and consensus on what
criteria should be applied to derive a representative healthy popula-
tion are required.
2. Additional studies assessing outcome-based cutoffs for the hs-cTn
assays for both diagnosis and prognosis. Research in patients with
stable coronary artery disease has suggested utility in risk stratiﬁca-
tion [10–13]; however, data is needed in the acute care setting in
various hospitalized patient groups at risk for myocardial injury [1,
14–18]. Speciﬁcally, outcome-based cutoffs (either alone or in
combination with clinical variables) that accurately identify
emergency department patients with symptoms of possible ACS
who are at short-term risk of adverse cardiac events are essential
for the appropriate identiﬁcation of emergency department patients
in need of admission for invasive coronary investigations.
3. Sex-speciﬁc cutoffs for diagnosis and prognosis. A large randomized
controlled trial is currently assessing the utility of sex-speciﬁc cutoffs
[19]. There are abundant data demonstrating differences in hs-cTn
between men and women [9,20,21], however, outcome data
assessing sex versus age-speciﬁc cutoffs are needed to understand
these two important variables [22,23].
4. Change in cardiac troponin concentrations (i.e., delta) has an impor-
tant role in understanding the (patho)physiological consequence of a
measurable concentration determined by the hs-cTn assays [24,25].
Criteria need to be established for each hs-cTn assay with an impor-
tant variable being the time between sampling and if measurements
are obtained early after pain onset as opposed to late presenters
[26–30].
5. The clinical utility and validity of single hs-cTn results in clinical
decision making [31–33]. It may be appropriate to use different
thresholds to rule out myocardial infarction than are currently
recommended for diagnosing myocardial infarction that would
permit earlier clinical decisions based on a single hs-cTn measure-
ment at presentation. However, the optimal threshold for ruling
out myocardial infarction and the reproducibility of hs-Tn assays at
thresholds below the 99th percentile are uncertain [34,35] and
such approaches have not been prospectively tested.
6. The pattern of release of hs-cTn after cardiac surgery including rate
and duration of rise, thresholds reached, and rate of fall that deter-
mine a pathological pattern versus normal post-operative process
for cardiac surgery is unknown. Speciﬁc type of cardiac surgery will
likely need to be accounted for as well; i.e. coronary bypass versus
intra-cardiac procedures [36].
There are many more areas that require additional research
assessing important analytical and clinical questions. However, the
above items represent areas where already much research performed
has led to a better understanding of hs-cTn assays. Further research
aimed at closing the gaps in hs-cTn testing will be needed beforeexcellent analytical sensitivity will equate to excellent clinical care for
patients being monitored with the hs-cTn assays.
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